These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 9935244)

  • 21. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
    Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
    Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
    Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity.
    Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
    Clin Exp Immunol; 1997 May; 108(2):352-7. PubMed ID: 9158110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
    Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
    J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
    da Costa L; Renner C; Hartmann F; Pfreundschuh M
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
    Eissler N; Ruf P; Mysliwietz J; Lindhofer H; Mocikat R
    Cancer Res; 2012 Aug; 72(16):3958-66. PubMed ID: 22745368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
    Manzke O; Titzer S; Tesch H; Diehl V; Bohlen H
    Cancer Immunol Immunother; 1997; 45(3-4):198-202. PubMed ID: 9435873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.
    Morecki S; Lindhofer H; Yacovlev E; Gelfand Y; Ruf P; Slavin S
    Exp Hematol; 2008 Aug; 36(8):997-1003. PubMed ID: 18495330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
    J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
    Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
    Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
    Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.
    Manzke O; Tesch H; Borchmann P; Wolf J; Lackner K; Gossmann A; Diehl V; Bohlen H
    Int J Cancer; 2001 Feb; 91(4):508-15. PubMed ID: 11251974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ; Hillstrom JR
    J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
    Wooldridge JE; Dahle CE; Weiner GJ
    Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.
    Manzke O; Berthold F; Huebel K; Tesch H; Diehl V; Bohlen H
    Int J Cancer; 1999 Mar; 80(5):715-22. PubMed ID: 10048973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
    Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H
    Int J Cancer; 2001 Feb; 91(4):516-22. PubMed ID: 11251975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Target cell-induced T cell activation with bi- and trispecific antibody fragments.
    Jung G; Freimann U; Von Marschall Z; Reisfeld RA; Wilmanns W
    Eur J Immunol; 1991 Oct; 21(10):2431-5. PubMed ID: 1655465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.